PEG9MA10-PAB10-GalMA10
PEG9MA10-PAB10-GalMA10 is a CD147 LYTAC degrader. PEG9MA10-PAB10-GalMA10 binds to the asialoglycoprotein receptor (ASGPR) via its galactose methacrylate domain, mediating its uptake by hepatoma cells. PEG9MA10-PAB10-GalMA10 induces lysosome-dependent degradation of CD147, resulting in concurrent loss of associated MCT1 and MCT4. PEG9MA10-PAB10-GalMA10 reduces extracellular lactate levels, increases intracellular lactate accumulation, inhibits glycolytic activity, and enhances mitochondrial respiratory capacity. PEG9MA10-PAB10-GalMA10 decreases the secretion of MMP-2 and MMP-9, and upregulates the expression of E-cadherin. PEG9MA10-PAB10-GalMA10 exhibits anti-tumor efficacy in hepatoma models. PEG9MA10-PAB10-GalMA10 can be used for research on liver cancer (hepatocellular carcinoma).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C690H1056N20O273S3
- 분자량:14095.93
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
MCT1 |
MCT4 |
MMP-2 |
MMP-9 |
In Vitro
PEG9MA10-PAB10-GalMA10 (10-40 μM; 48 h) induces dose-dependent degradation of CD147 in HepG2 cells, and its level decreases to 49% of that in the control group after treatment with 40 μM for 48 h[1].
PEG9MA10-PAB10-GalMA10 (5-20 μM; 48 h) induces dose-dependent degradation of CD147 in H22 cells, with its level decreasing to 39% of that in the control group after treatment with 20 μM for 48 h[1].
PEG9MA10-PAB10-GalMA10 (20 μM) promotes lysosomal colocalization and degradation of CD147, MCT1 and MCT4 in Hepa1-6 cells[1].
PEG9MA10-PAB10-GalMA10 increases intracellular lactate levels and decreases extracellular lactate levels in Hepa1-6 cells under both normoxic and hypoxic conditions, indicating impaired lactate efflux[1].
PEG9MA10-PAB10-GalMA10 inhibits glycolytic activity (reduces maximal ECAR) and enhances mitochondrial respiratory capacity (increases maximal OCR) in Hepa1-6 cells[1].
PEG9MA10-PAB10-GalMA10 (12-48 h) significantly inhibits the migration of Hepa1-6 cells in scratch wound healing assays[1].
PEG9MA10-PAB10-GalMA10 reduces the secretion of MMP-2 and MMP-9 in Hepa1-6 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 human hepatocellular carcinoma cells
-
Concentration:0, 10, 20, 40 μM
-
Incubation Time:48 h
-
Result:Reduced CD147 levels to 97%, 74%, and 49% of control at 10, 20, 40 μM after 48 h, respectively.
-
Cell Line:H22 murine liver cancer cells
-
Concentration:0, 5, 20 μM
-
Incubation Time:48 h
-
Result:Reduced CD147 levels to 89% and 39% of control at 5, 20 μM after 48 h, respectively.
In Vivo
PEG9MA10-PAB10-GalMA10 (40 mg/kg; administered via intratracheal injection; 4 doses given on days 0, 3, 6, and 9) potently inhibits the growth of subcutaneous Hepa1-6-GFP tumors in female C57BL/6 mice via selective degradation of CD147 in tumor cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 6-8 weeks old, subcutaneous injection of 2×106 H22 cells)[1]
-
Dosage:40 mg/kg
-
Administration:i.t.; 4 doses on days 0, 3, 6, 9
-
Result:Suppressed tumour growth compared to controls.
Prolonged survival compared to controls.
Reduced intra-tumoural lactate levels.
Selectively degraded CD147 in CD45- tumour cells (no effect on CD45+ immune cells).
Showed no significant body weight loss.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, subcutaneous injection of 2×106 Hepa1-6-GFP cells)[1]
-
Dosage:40 mg/kg
-
Administration:i.t.; 4 doses on days 0, 3, 6, 9
-
Result:Suppressed tumour growth, with reduced tumour volume compared to controls.
Showed no significant body weight loss.
Selectively degraded CD147 in CD45- GFP+ tumour cells (no effect on CD45+ GFP- immune/stromal cells).
Chemical Information
-
분자량 14095.93
-
화학식 C690H1056N20O273S3
-
SMILES
CCCCCCCCCCCCSC(SC(C(NC1=CC=C(O[C@H](O2)[C@H](O)[C@@H](O)[C@@H](O)[C@H]2CO)C=C1)=O)(C)CC(C(NC3=CC=C(O[C@H](O4)[C@H](O)[C@@H](O)[C@@H](O)[C@H]4CO)C=C3)=O)(C)CC(C(NC5=CC=C(O[C@H](O6)[C@H](O)[C@@H](O)[C@@H](O)[C@H]6CO)C=C5)=O)(C)CC(C(NC7=CC=C(O[C@H](O8)[C@H](O)[C@@H](O)[C@@H](O)[C@H]8CO)C=C7)=O)(C)CC(C(NC9=CC=C(O[C@H](O%10)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%10CO)C=C9)=O)(C)CC(C(NC%11=CC=C(O[C@H](O%12)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%12CO)C=C%11)=O)(C)CC(C(NC%13=CC=C(O[C@H](O%14)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%14CO)C=C%13)=O)(C)CC(C(NC%15=CC=C(O[C@H](O%16)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%16CO)C=C%15)=O)(C)CC(C(NC%17=CC=C(O[C@H](O%18)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%18CO)C=C%17)=O)(C)CC(C(NC%19=CC=C(O[C@H](O%20)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%20CO)C=C%19)=O)(C)CC(CC(CC(CC(CC(CC(CC(CC(CC(C(OCCNC(/C(C)=C/C=C/C(C)(OC%21=O)C(C%22(CC%23)OC(C)=O)CCC%21%22CC=C%23C(OC)=O)=O)=O)(CC(CC(CC(CC(CC(CC(CC(CC(CC(CC(CC(C#N)(CCC(O)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%24=O)C(C%25(CC%26)OC(C)=O)CCC%24%25CC=C%26C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%27=O)C(C%28(CC%29)OC(C)=O)CCC%27%28CC=C%29C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%30=O)C(C%31(CC%32)OC(C)=O)CCC%30%31CC=C%32C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%33=O)C(C%34(CC%35)OC(C)=O)CCC%33%34CC=C%35C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%36=O)C(C%37(CC%38)OC(C)=O)CCC%36%37CC=C%38C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%39=O)C(C%40(CC%41)OC(C)=O)CCC%39%40CC=C%41C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%42=O)C(C%43(CC%44)OC(C)=O)CCC%42%43CC=C%44C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%45=O)C(C%46(CC%47)OC(C)=O)CCC%45%46CC=C%47C(OC)=O)=O)=O)C)=S
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)